13F Pro13F Pro

ADAR1 Capital Management, LLC

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1940272
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare88.6%$1.9B
  • Other9.4%$201.1M
  • Financials1.7%$36.4M
  • Consumer Staples0.1%$1.9M
  • Real Estate0.1%$1.0M
  • Technology0.1%$1.0M
  • Consumer Discretionary0.0%$955,150
  • Industrials0.0%$651,736

AUM History

13fpro.ai/research/fund/adar1-capital-management-llc-1940272

Conviction and streaks

Concentrating · top 10 = 41.9%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

ABVX$ABVXConviction hold11.3% weight · held 10 quartersPTGX$PTGXConviction hold5.5% weight · held 10 quartersROIV$ROIVConviction hold5.3% weight · held 10 quartersSPY$SPYConviction hold4.5% weight · held 5 quartersIMVT$IMVTConviction hold4.2% weight · held 10 quartersCRNX$CRNXAccumulating+2200% shares · 4 quarters runningNKTR$NKTRAccumulating+1446% shares · 4 quarters runningPEPG$PEPGAccumulating+12631% shares · 4 quarters runningPLRX$PLRXAccumulating+6604% shares · 3 quarters runningCATX$CATXAccumulating+1629% shares · 3 quarters runningRZLT$RZLTTrimming-98% shares · 8 quarters runningPTGX$PTGXTrimming-54% shares · 2 quarters runningROIV$ROIVTrimming-54% shares · 2 quarters runningIMVT$IMVTTrimming-53% shares · 2 quarters runningCYTK$CYTKTrimming-58% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/adar1-capital-management-llc-1940272

ADAR1 Capital Management, LLC 13F holdings — Q2 2026

$2.2B portfolio (+28.6% QoQ) · 277 holdings · Q2 2026 13F · top 10 are 42% of the stock portfolio

Includes $57.7M of put/call options ($48.8M puts, $8.8M calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $2.1B. Weights use the stock portfolio.

All holdings — ADAR1 Capital Management, LLC (Q2 2026)

277 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
SEPN$SEPNSepterna, Inc.$31.5M-14%
AVR$AVRAnteris Technologies Global Corp.$31.0M-17%
EDIT$EDITEditas Medicine, Inc.$28.8MNew
DNLI$DNLIDenali Therapeutics Inc.$26.5M-45%
SYRE$SYRESpyre Therapeutics, Inc.$25.2M-16%
VIR$VIRVir Biotechnology, Inc.$25.0M-10%
PRAX$PRAXPraxis Precision Medicines, Inc.$24.9M+4850%
INSM$INSMINSMED Inc$24.4M+546%
CLDX$CLDXCelldex Therapeutics, Inc.$23.1M+45%
VKTX$VKTXViking Therapeutics, Inc.$22.4M+152%
TSHA$TSHATaysha Gene Therapies, Inc.$20.7M+2%
MNPR$MNPRMonopar Therapeutics$20.1M-18%
OVID$OVIDOvid Therapeutics Inc.$20.0M+63%
ELVN$ELVNEnliven Therapeutics, Inc.$19.7M+18%
ENTA$ENTAENANTA PHARMACEUTICALS INC$19.6M+2518%

What changed in Q2 2026

Against the previous quarter's 13F: 43 new, 102 added to, 64 trimmed, 76 sold out. Share-count changes; largest moves by dollar size first.

New positions (43)

  • EDIT$EDITEditas Medicine, Inc.$28.8M

    first bought this quarter

  • SPY$SPYPUTSPDR S&P 500 ETF TRUST$18.7M

    first bought this quarter

  • VOR$VORVor Biopharma Inc.$12.5M

    first bought this quarter

  • FAETH THERAPEUTICS INC - COM NEW$9.0M

    first bought this quarter

  • AMAN$AMANAmanat Acquisition Corp.$7.6M

    first bought this quarter

  • RACC$RACCResearch Alliance Corp III$7.0M

    first bought this quarter

+37 more in the Excel export

Added to (102)

  • ABVX$ABVXAbivax S.A.+29%

    now $240.5M · held 2+ qtrs

  • AGIO$AGIOAGIOS PHARMACEUTICALS, INC.+816%

    now $47.8M · held 2+ qtrs

  • SPY$SPYSPDR S&P 500 ETF TRUST+70%

    now $96.4M · held 2+ qtrs

  • ZLAB$ZLABZai Lab Ltd+136%

    now $64.0M · held 2+ qtrs

  • PRAX$PRAXPraxis Precision Medicines, Inc.+4850%

    now $24.9M · held 2+ qtrs

  • INSM$INSMINSMED Inc+546%

    now $24.4M · held 2+ qtrs

+96 more in the Excel export

Trimmed (64)

  • DNLI$DNLIDenali Therapeutics Inc.-45%

    now $26.5M · held 2+ qtrs

  • CYTK$CYTKCYTOKINETICS INC-28%

    now $39.0M · held 2+ qtrs

  • IMVT$IMVTImmunovant, Inc.-13%

    now $89.8M · held 2+ qtrs

  • MPLT$MPLTMapLight Therapeutics, Inc.-93%

    now $950K

  • SNY$SNYSanofi-82%

    now $2.4M · held 2+ qtrs

  • REPL$REPLReplimune Group, Inc.-59%

    now $7.3M · held 2+ qtrs

+58 more in the Excel export

Sold out (76)

  • TERN$TERNTerns Pharmaceuticals, Inc.was $48.2M

    held 4+ qtrs

  • BEAM$BEAMBeam Therapeutics Inc.was $34.5M

    held 1+ qtrs

  • SRRK$SRRKScholar Rock Holding Corpwas $20.0M

    held 8+ qtrs

  • TERN$TERNCALLTerns Pharmaceuticals, Inc.was $10.5M
  • VRTX$VRTXVERTEX PHARMACEUTICALS INC / MAwas $6.7M

    held 3+ qtrs

  • VRDN$VRDNViridian Therapeutics, Inc.\DEwas $6.0M

    held 9+ qtrs

+70 more in the Excel export

Firm AUM (Form ADV): $1.7B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F ADAR1 Capital Management, LLC has filed, 10 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow ADAR1 Capital Management?

Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of ADAR1 Capital Management's top 20 holdings: 24/100 (our AI quality score, weighted by position size; 10 of the 20 are scored)

Top 10 since filing

-13.9%

Value-weighted move of the 10 largest stock positions

Turnover

21%

Last quarter

Top 10 weight

42%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

0%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2026 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

ADAR1 Capital Management, LLC disclosed 277 positions worth $2.2B in its Form 13F-HR for Q2 2026 — $2.1B in common stock plus $57.7M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ABVX (Abivax S.A.) at 11.3% of the equity portfolio, followed by $PTGX and $ROIV. During the quarter the fund opened 43 new positions and exited 76 — including a new stake in $EDIT and a full exit from $TERN. The portfolio is most concentrated in Healthcare (88.6% of disclosed assets). All figures are sourced directly from ADAR1 Capital Management, LLC’s Form 13F-HR filing with the SEC under CIK 1940272.

Funds like this

managers whose biggest positions overlap ADAR1 Capital Management's
TCG Crossover Management, LLC$4.16B 13F book · 7 shared top holdingsABVXIMVTZLABSYREFARALLON CAPITAL MANAGEMENT LLC$21.68B 13F book · 7 shared top holdingsPTGXROIVCRNXIMVTAffinity Asset Advisors, LLC$2.21B 13F book · 13 shared top holdingsROIVABVXCYTKSYRERTW INVESTMENTS, LP$11.71B 13F book · 9 shared top holdingsPTGXCYTKSYREINSMDarwin Global Management, Ltd.$3.76B 13F book · 4 shared top holdingsABVXROIVINSMRVMDPERCEPTIVE ADVISORS LLC$6.66B 13F book · 11 shared top holdingsROIVPTGXSYREPRAX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: ADAR1 Capital Management, LLC

13F Pro is an AI hedge fund tracker and stock research platform. For ADAR1 Capital Management, LLC (SEC CIK: 1940272), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in ADAR1 Capital Management, LLC's portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.